US EditionNSABP B-64/ EXActDNA-003 Breast Cancer Clinical Validation Study
Summary by Rush University Medical Center
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
NSABP B-64/ EXActDNA-003 Breast Cancer Clinical Validation Study
NSABP B-64/ EXActDNA-003 Breast Cancer Clinical Validation Study abernotas Fri, 03/28/2025 - 12:28 Clinical Trial EXActDNA-003: Breast Cancer Clinical Validation Study to Predict Recurrence of High-Risk Early Breast Cancer Treated with Neoadjuvant Therapy Using a Bespoke Circulating Tumor DNA Assay to Detect Molecular Residual Disease (NSABP B-64) Rush University Medical Center The Sponsor of this study is developing a lab test (called Oncodetec…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
